The therapeutic effectiveness of JAK inhibitors in managing psoriasis primarily stems from their capacity to disrupt the JAK/STAT signaling pathway, which plays a pivotal role in mediating pro-inflammatory cytokine signals that contribute to KCs hyperproliferation and sustained inflammation [68]. Here, TBCE is linked to psoriasis.